Evolus, Inc. (NASDAQ:EOLS) Insider Sells $24,434.20 in Stock

Evolus, Inc. (NASDAQ:EOLS) insider Rui Avelar sold 2,252 shares of the stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $10.85, for a total transaction of $24,434.20. Following the completion of the sale, the insider now directly owns 366,595 shares of the company’s stock, valued at approximately $3,977,555.75. This trade represents a 0.61 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Evolus Price Performance

Shares of Evolus stock opened at $11.09 on Friday. The firm has a market cap of $702.23 million, a P/E ratio of -12.19 and a beta of 1.27. The firm’s 50-day simple moving average is $13.35 and its 200-day simple moving average is $13.73. Evolus, Inc. has a twelve month low of $9.80 and a twelve month high of $17.82. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47.

Institutional Investors Weigh In On Evolus

A number of institutional investors have recently added to or reduced their stakes in the stock. Quest Partners LLC bought a new position in shares of Evolus during the 2nd quarter worth approximately $43,000. Quarry LP acquired a new position in Evolus during the second quarter worth $54,000. Point72 Asset Management L.P. bought a new position in shares of Evolus during the third quarter valued at $132,000. Dynamic Technology Lab Private Ltd bought a new position in shares of Evolus during the third quarter valued at $191,000. Finally, Profund Advisors LLC bought a new position in shares of Evolus during the second quarter valued at $130,000. 90.69% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have recently commented on EOLS. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Evolus in a research report on Monday, September 16th. Barclays upped their price target on Evolus from $16.00 to $20.00 and gave the company an “overweight” rating in a report on Friday, September 13th. HC Wainwright restated a “buy” rating and set a $27.00 price objective on shares of Evolus in a research report on Thursday, November 7th. Finally, Needham & Company LLC restated a “buy” rating and issued a $22.00 target price on shares of Evolus in a research note on Friday, September 13th.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.